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ABSTRACT
Objectives: Tackling the harm associated with acute
kidney injury (AKI) is a global priority. In England, a
national computerised AKI algorithm is being
introduced across the National Health Service (NHS) to
drive this change. The study sought to maximise its
clinical utility and minimise the potential for burden on
clinicians and patients in primary care.
Design: An appropriateness ratings evaluation using
the RAND/UCLA Appropriateness Method.
Setting: Clinical scenarios were developed to test the
timeliness in (1) communication of AKI warning stage
test results from clinical pathology services to primary
care, and (2) primary care clinician response to an AKI
warning stage test result.
Participants: A 10-person panel was purposively
sampled with representation from clinical biochemistry,
acute and emergency medicine and general practice.
General practitioners (GPs) represented typical practice
in relation to rural and urban practice, out of hours
care, GP commissioning and those interested in
reducing the impact of medicalisation and
‘overdiagnosis’.
Results: There was agreement that delivery of AKI
warning stage test results through interruptive methods
of communication (ie, telephone) from laboratories to
primary care was the appropriate next step for patients
with an AKI warning stage 3 test result. In the context
of acute illness, waiting up to 72 hours to respond to
an AKI warning stage test result was deemed an
inappropriate action in 62 out of the 65 (94.5%) cases.
There was agreement that a clinician response was
required within 6 hours, or less, in 39 out of 40
(97.5%) clinical cases relating AKI warning stage test
results in the presence of moderate hyperkalaemia.
Conclusions: The study has informed national
guidance to support a timely and calibrated response
to AKI warning stage test results for adults in primary
care. Further research is needed to support effective
implementation, with a view to examine the effect on
health outcomes and costs.
INTRODUCTION
Maintenance of kidney health is central to
addressing two global health priorities: the
prevention of cardiovascular disease and
support for people vulnerable to complica-
tions during episodes of acute illness.1–4 The
international 0by25 initiative (http://www.
0by25.org/) aims to prevent avoidable harm
associated with acute kidney injury (AKI).2
In a similar vein, the National Health Service
(NHS) Five Year Forward View emphasises
tackling AKI as a priority to improve patient
safety and health outcomes across the NHS.5
AKI is a clinical syndrome characterised by
a sudden reduction in kidney function.4 The
diagnosis of AKI and its staging is based on
acute changes in serum creatinine and/or a
Strengths and limitations of this study
▪ The study used systematic RAND/UCLA consen-
sus methods to optimise clinician response to
acute kidney injury (AKI) warning stage test
results for adults in primary care.
▪ Efforts to maximise the utility of AKI alerts and
minimise the potential for burden included
engagement with general practitioners who
represented concerns about medicalisation and
overdiagnosis.
▪ Although a range of clinically relevant scenarios
were considered, in terms of burden on RAND/
UCLA panellists, it was not feasible to test all
major comorbidity groups (eg, patients with type
2 diabetes).
▪ The study sought clarity on ‘necessary’ actions
required under ideal conditions and further
studies are needed to understand the implemen-
tation of AKI alerts and guidance in routine
clinical practice.
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reduction in urine output.4 There are many causes for
AKI though it is most commonly associated with epi-
sodes of acute illness on the background of increased
risk.4 6–8 AKI is associated with frailty and is more
common in older people living with complex comorbid-
ities.4 6 8–12 These include people with pre-existing
chronic kidney disease (CKD), diabetes and heart
failure as well as those with underlying cognitive decline,
who may be reliant on a carer for adequate fluid intake
during episodes of acute illness.6
AKI is associated with ∼1 in 5 unplanned hospital
admissions, with almost two-thirds of these patients with
AKI having developed it in the community.13 It is asso-
ciated with increased length of hospital admission and
need for renal replacement therapy.4 AKI is also asso-
ciated with poorer health outcomes including increased
risk of progression of CKD and increased mortality both
in the short and long terms.4 Care of people with AKI
costs around 1% of the NHS budget, reflecting the fact
that AKI is a strong marker for severity of acute illness.14
In a major NHS England patient safety initiative, a
computerised AKI algorithm has been established,
based on the Kidney Disease Improving Global
Outcomes (KDIGO) classification system for AKI, to
automatically detect biochemical changes in kidney
function and identify potential cases of AKI.4 15 16 The
test result is named an ‘AKI warning stage’ and is cate-
gorised according to severity (ie, AKI stage 1, 2 or 3).15
A level 3 NHS England Patient Safety Notice made it
mandatory that all NHS Acute Trusts and Foundation
Trusts implement the use of the algorithm within labora-
tory information systems, providing warning stage results
to users in secondary care, by March 2015. This is com-
bined with a mandatory submission of a data set to a
national registry allowing audit of the frequency of
alerts.16 The next phase of AKI alerting involves direct
communication of AKI warning stage test results to
primary care in England, from April 2016.15 16
National clinical guidelines for AKI recommend ‘iden-
tifying AKI in patients with acute illness’ who are
deemed at risk of AKI.6 At present, while a significant
proportion of episodes of illness complicated by AKI
start in the community, AKI tends to be identified on
hospital admission.17 As a potential marker of the ‘sick
patient’, this new test could support earlier detection
and prompt management of acute illness in primary
care.15 18 However, trade-offs exist between their clinical
utility and the potential for burden on clinical care.19 20
First, kidney function tests are taken in primary care
for many reasons both as part of routine disease man-
agement monitoring as well as assessment of urgent
care. Current data suggest that only a small proportion
of all primary care serum creatinine requests generate
an AKI alert.21 In primary care, a decision on whether
or not to check kidney function needs to be tailored to
the individual circumstance.6 Consideration needs to be
given as to whether this will support clinical manage-
ment. For example, blood tests are not necessary when
immediate admission is required (eg, there is evidence
of sepsis).22 23 At the other end of the spectrum, check-
ing kidney function tests may also not be necessary for
patients presenting with a minor self-limiting acute
illness, such as a single episode of diarrhoea or
vomiting.
Second, ‘false-positive’ test results may occur. For
example, a change in serum creatinine may be due to
progression of CKD rather than represent an acute
deterioration in kidney function.15 19 20 Third, there is
also need to address the risks associated with a test result
being communicated from laboratories to out of hours
services, requiring a clinician who may have limited
access to clinical information to act on the result.
Fourth, there is evidence to suggest that the introduc-
tion of ‘e-alerts’ in isolation are unlikely to improve
health outcomes.24 25 In particular, ‘alert fatigue’ is a
recognised problem limiting implementation and effect-
iveness.26 27 If implemented well, the release of AKI
warning stage test results to primary care has the poten-
tial to generate major improvements in outcomes.
However, experience of other ‘top-down’ initiatives
intended to improve kidney outcomes in primary care
has been mixed.28
In order to maximise their clinical utility and minim-
ise burden on health professionals and patients, guid-
ance is required to ensure a timely response and for test
results to be considered with an understanding of the
clinical context in which the blood test was taken.
METHODS
Study design
The RAND/UCLA Appropriateness Method (RAM) was
used to help develop guidance on the response to AKI
warning stage test results in primary care.29 RAM is an
established consensus method to generate appropriate-
ness ratings.29 It is a systematic approach to address spe-
cific dilemmas in clinical practice in which clinical
decisions are required but where ‘robust scientific evi-
dence’ about the benefits is lacking.29–31 The methodo-
logy combines ‘best available scientific evidence with the
collective judgement of experts’ in order to provide a
statement regarding the appropriateness of undertaking
a particular action ‘at the level of patient-specific symp-
toms, medical history and tests results’.29–31 As such, it is
a rigorous methodology congruent with a need to place
response to AKI warning stage test results in clinical
context. Findings from the process are deemed to have
face validity and provide a platform for prospective
development and evaluation of guidance to support clin-
ical decision-making.32
Developing clinical scenarios for appropriateness rating
Through NHS England’s Think Kidneys Programme, a
working group was established to develop clinical scen-
arios for appropriateness rating.33 In order to ensure
scenarios were informed from a range of perspectives,
2 Blakeman T, et al. BMJ Open 2016;6:e012865. doi:10.1136/bmjopen-2016-012865
Open Access
group.bmj.com on April 20, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
the group comprised general practitioners (GPs), a
nephrologist, a chemical pathologist with a GP back-
ground and a methodologist with expertise in the RAM
as well as patient safety in primary care. The group iden-
tified national AKI clinical guidelines and invited hospital
trusts, clinical commissioning groups and strategic clinical
networks throughout the country to send guidance docu-
ments in use, or being developed, to support primary
care in responding to AKI warning stage test results.
These documents were reviewed to identify key elements
of care relating to AKI, which through group discussion
led to the generation of a list of clinical cases, with a
focus on rating the timeliness in response to each case.
Clinical scenarios were categorised according to the
following clinical characteristics: level of AKI warning
stage test result (AKI warning stage 1, 2 and 3); medical
history (episode of acute illness, history of chronic heart
failure, CKD stage 4 or 5, or history of renal transplant,
recent change in dose of a diuretic, ACE inhibitor or
angiotensin receptor blocker); and evidence of com-
plicating factors (poor fluid intake/urine output, hyper-
kalaemia, both mild (K 5.5–5.9 mmol/L) or moderate
(K 6.0–6.4 mmol/L), evidence of risk of urinary tract
obstruction or intrinsic renal disease). Scenarios were
not tested for severe hyperkalaemia as UK Renal
Association Clinical Practice Guidelines recommend
emergency assessment and treatment of severe hyperka-
laemia (K+≥6.5 mmol/L).34 In order to reduce research
burden on panel members and keep the process salient,
a decision was made to restrict the number of ratings for
AKI warning stage 3 test results in which timeliness in
management was deemed less controversial.4 Also, the
clinical scenarios considered during the consensus
process were not specific to either in hours or out of
hours care. Other categories considered in scenarios
presented were: age (adult, or children and young
person); and whether a patient was receiving end of life
care. These clinical characteristics were then used to
develop 163 clinical cases, with four responses (next
steps) requiring rating for each clinical case (ie,
163×4=652 clinical scenarios).
Each clinical case represented a separate testing indi-
cation consisting of variable combinations of the clinical
characteristics. Clinical cases were independently linked
to two main areas of decision-making:
1 Based on knowledge of an AKI warning stage test
result and potassium level, clinical pathology service/
laboratory staff need to make one of four decisions:
▸ Send an AKI warning stage result via the data trans-
fer service without comment (non-interruptive
communication).
▸ Send an AKI warning stage result via the data trans-
fer service with comment (non-interruptive
communication).
▸ Send an AKI warning stage result to an NHS
email address that is known to be monitored
regularly during working hours (non-interruptive
communication).
▸ Send an AKI warning stage result by telephone call
to GP/practice/out of hours service provider (inter-
ruptive communication).
2 Based on the knowledge of the presenting AKI
warning stage test result, clinical history including
complications, GPs (responsible primary care team,
ie, either in hours or out of hours service provider)
will need to make one of four decisions:
▸ Seek immediate admission.
▸ Respond to the AKI warning stage result within
6 hours.
▸ Respond to the AKI warning stage result within
24 hours.
▸ Respond to the AKI warning stage result within
72 hours.
An established rating scale was used to rate each
potential decision for each clinical scenario on a nine-
point integer scale, with 1 indicating an ‘extremely
inappropriate next step’ and 9 indicating an ‘extremely
appropriate next step’:29 31
▸ Scores 1–3: inappropriate next step (ie, no benefit,
possible harms).
▸ Scores 4–6: uncertainty about next step (ie, when
harms and benefits are judged as approximately
equal, or when the best available evidence does not
support a judgement either way).
▸ Scores 7–9: Appropriate next step (ie, benefits judged
to outweigh harms).
Panel membership and rating
Panel members were purposively sampled and recruited
to ensure that a range of perspectives were considered
and ensure that the appropriateness ratings were valid
for routine clinical general practice. A 10-person panel
was identified with representation from clinical bio-
chemistry (n=2), acute and emergency medicine (n=2)
and general practice (GP principals, n=5; salaried GP,
n=1). Individuals with an expressed interest and expert-
ise in AKI through membership of the NHS England
Think Kidneys Programme were invited as well as GPs
who represented typical practice in relation to out of
hours care, rural and urban practice, GP commissioning
and those with an interest in reducing medicalisation
and ‘overdiagnosis’.33 35 The panel was co-chaired by
one researcher (SC), who is expert in the RAM, and a
nephrologist (CT) who is expert in AKI, neither of
whom contributed to the RAND/UCLA decision-making
scores.
The RAND process entailed two rounds of rating:
Round 1 was conducted by email with the panel
members rating the clinical scenarios individually at
home, with no discussion between panellists. In order to
help rate the appropriateness of each decision for every
scenario, panel members were sent an ‘instructions’
document and a ‘context’ document that provided an
overview of the literature with a focus on the rationale
for the clinical characteristics chosen. The evaluation
aimed to gain clarity on ‘necessary’ processes of care
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under ideal conditions. When scoring each scenario,
panellists were instructed to assume that they had avail-
able all the clinical information presented.
Round 2 entailed a 1-day face-to-face meeting held in
September 2015. Panel members were presented with
their own data from round 1 as well as data outlining
the distribution of all panel members’ ratings. This
summary was used to stimulate discussion with a focus
on areas of disagreement. Panel members then rated
each scenario on their own individual-blinded rating
sheets. Panel members were not required to reach
consensus.
Data entry and analysis
RAMs were used to conduct analysis.29 Data from round
2 were collated and analysed to determine the level of
agreement within the panel for a proposed action for
each clinical scenario. Agreement was defined by 8 out
the 10 (80%) panel members rating the same three-
point region on the nine-point integer scale (ie, 1–3, 4–
6, 7–9). Disagreement was defined to exist where ≥30%
of panel members rated a scenario in the 1–3 range and
where ≥30% rated the same scenario in the 7–9 range
on the nine-point integer scale. A proposed action was
then categorised as an ‘appropriate’ next step if a scen-
ario rated 7–9 without disagreement and a rating of 1–3
without disagreement was deemed to be an ‘inappropri-
ate’ next step. Ratings of clinical scenarios without con-
sensus (either ‘agreement’ or ‘disagreement’) were
considered as equivocal.
RESULTS
The results are presented in tables 1–4 for round 2
ratings. Table 1 summarises the ratings across the 652
clinical scenarios, with 415 (63.7%) achieving agree-
ment; 32 (4.9%) rated with disagreement and 205
(31.4%) with an equivocal rating. A proposed action was
deemed the appropriate next step in 137 (21.0%) out of
the 652 scenarios. Two hundred and ten (32.2%) of the
proposed actions were deemed inappropriate, and in 68
Table 1 Summary of round 2 appropriateness ratings
Total number of scenarios 652
Agreement (8 out of 10 (80%) of panel
members rating in the same 3-point region)
415 (63.7%)
Appropriate (80% of panel members rating
7–9)
137 (21.0%)
Inappropriate (80% of panel members rating
1–3)
210 (32.2%)
Agreement with uncertain benefit (80% of
panel members rating the same consecutive
3-point region—but NOT 1–3 or 7–9)
68 (10.4%)
Disagreement (≥30% of scores in 1–3 AND
≥30% in 7–9 for same scenario)
32 (4.9%)
Equivocal 205 (31.4%) Ta
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Table 3 Timeliness in response to AKI warning stage test results for adults in primary care—in the context of acute illness
AKI warning stage 1 AKI warning stage 2 AKI warning stage 3
AKI in the context of
acute illness
No
comorbidities
Chronic
heart
failure
CKD 4/5 or
renal
transplant
CKD 4/5
and chronic
heart failure
No
comorbidities
Chronic
heart
failure
CKD 4/5 or
renal
transplant
CKD 4/5 and
chronic
heart failure
No
comorbidities
Chronic
heart
failure
CKD 4/5 or
renal
transplant
CKD 4/5
and chronic
heart failure
Potassium not raised SIA=A(2)
<6=D(5.5)
<24=E(7)
<72=E(5)
SIA=E(3)
<6=D(6)
<24=A(7)
<72=E(2.5)
SIA=(4.5)
<6=U(7)
<24=A(7.5)
<72=A(1)
SIA=(4.5)
<6=U(7)
<24=E(5.5)
<72=A(1)
SIA=E(4.5)
<6=A(7)
<24=E(7)
<72=A(1)
SIA=E(5)
<6=U(7.5)
<24=U(6)
<72=A(1)
SIA=E(5)
<6=A(7)
<24=D(5.5)
<72=A(1)
SIA=E(7)
<6=A(8)
<24=E(4)
<72=A(1)
SIA=A (8)
<6=U(7)
<24=A(1)
<72=A(1)
Not tested Not tested Not tested
Mild hyperkalaemia
(5.5–5.9mmol/L)
SIA=E(3.5)
<6=E(7)
<24=A(7)
<72=E(3)
SIA=E(4.5)
<6=U(7)
<24=U(6.5)
<72=A(1.5)
SIA=E(5)
<6=A(7.5)
<24=E(6)
<72=A(1)
SIA=U(5.5)
<6=A(7)
<24=E(4)
<72=A(1)
SIA=E(5)
<6=A(8)
<24=U(7)
<72=A(1)
SIA=U(6)
<6=A(7.5)
<24=E(5.5)
<72=A(1)
SIA=U(6)
<6=A(8)
<24=E(3)
<72=A(1)
SIA=A(7)
<6=A(7)
Not tested Not tested Not tested Not tested
<24=U(3)
<72=A(1)
Moderate
hyperkalaemia
(6.0–6.4 mmol/L)
SIA=E(6)
<6=A(8)
<24=E(5)
<72=A(1)
SIA=D(5.5)
<6=A(7)
<24=E(5)
<72=A(1)
SIA=E(7)
<6=A(7.5)
<24=E(2.5)
<72=A(1)
SIA=A(8)
<6=U(6.5)
<24=A(2)
<72=A(1)
SIA=A(7.5)
<6=E(8)
<24=A(3)
<72=A(1)
SIA=A(7)
<6=A(8)
SIA=A(7.5)
<6=U(7)
<24=A(3)
<72=A(1)
SIA=A(8)
<6=U(7)
<24=A(2)
<72=A(1)
Not tested Not tested Not tested Not tested
<24=U(3)
<72=A(1)
Risk of urinary tract
obstruction or intrinsic
renal disease
SIA=E(7)
<6=A(7.5)
<24=E(5)
<72=A(1)
SIA=E(6.5)
<6=E(6.5)
<24=D(7)
<72=A(1)
SIA=E(7.5)
<6=E(7)
<24=E(6)
<72=A(1)
SIA=A(8)
<6=E(7)
<24=E(2)
<72=A(1)
SIA=A(7)
<6=E(7)
<24=E(4.5)
<72=A(1)
SIA=E(7)
<6=U(7)
<24=E(6)
<72=A(1)
SIA=U(7)
<6=E(7)
<24=A(3)
<72=A(1)
SIA=A(7.5)
<6=E(7)
<24=A(2)
<72=A(1)
Not tested Not tested Not tested Not tested
Poor oral intake/urine
output
SIA=E(4)
<6=A(7)
<24=E(7)
<72=A(1.5)
SIA=E(4)
<6=U(7)
<24=E(7)
<72=A(2)
SIA=E(4.5)
<6=A(7)
<24=U(7)
<72=A(1.5)
SIA=E(6)
<6=U(7)
<24=E(5)
<72=A(1)
SIA=U(7)
<6=A(7)
<24=E(4)
<72=A(1)
SIA=E(6)
<6=A(7)
<24=E(5.5)
<72=A(1)
SIA=U(6)
<6=A(8)
<24=U(3)
<72=A(1)
SIA=U(7)
<6=A(8)
<24=E(3.5)
<72=A(1)
Not tested Not tested Not tested Not tested
Mild hyperkalaemia
+poor oral intake/urine
output
SIA=U(5)
<6=A(7)
<24=D(6)
<72=A(1)
SIA=U(5)
<6=E(7)
<24=E(7)
<72=A(1)
SIA=U(6)
<6=A(7)
<24=D(5)
<72=A(1)
SIA U(6.5)
<6=U(7)
<24=A(2)
<72=A(1)
SIA=U(7)
<6=A(8)
<24=E(4.5
<72=A(1)
SIA=E(6.5)
<6=A(8)
<24=U(3.5)
<72=A(1)
SIA=U(7)
<6=A(8)
<24=E(3)
<72=A(1)
SIA=A(7)
<6=A(8)
Not tested Not tested Not tested Not tested
<24=A(2)
<72=A(1)
Moderate
hyperkalaemia+poor
oral intake/urine output
SIA=A(7)
<6=A(8)
SIA=E(7)
<6=E(7)
<24=E(3)
<72=A(1)
SIA=A(8)
<6=E(7)
<24=E(3)
<72=A(1)
SIA=A(9)
<6=D(5.5)
<24=A(2)
<72=A(1)
SIA=A(9)
<6=U(7)
<24=A(2.5)
<72=A(1)
SIA=A(8)
<6=U(7)
<24=A(2.5)
<72=A(1)
SIA=A(8.5)
<6=E(6.5)
<24=A(2)
<72=A(1)
SIA=A(9)
<6=E(6.5)
<24=A(1.5)
<72=A(1)
Not tested Not tested Not tested Not tested
<24=A(2.5)
<72=A(1)
Risk urinary tract
obstruction or intrinsic
renal disease+poor oral
intake/urine output
SIA=E(7.5)
<6=E(7.5)
<24=E(3)
<72=A(1)
SIA=E(6.5)
<6=E(5.5)
<24=D(3.5)
<72=A(1)
SIA=E(7.5)
<6=E(6.5)
<24=D(1.5)
<72=A(1)
SIA=A(8)
<6=A(7)
SIA=E(8)
<6=E(6.5)
<24=E(3)
<72=A(1)
SIA=A(7.5)
<6=E(6.5)
<24=E(3)
<72=A(1)
SIA=A(8)
<6=E(7)
<24=A(2)
<72=A(1)
SIA=A(8)
<6=E(7)
<24=A(2)
<72=A(1)
Not tested Not tested Not tested Not tested
<24=A(2)
<72=A(1)
Colour key: red: agreement that seeking immediate admission is an appropriate action; orange: agreement that responding in <6 hours is an appropriate action; brown: agreement that
responding in <24 hours is an appropriate action; no colour: no agreement on an appropriate action. Numerical value in brackets: median rating.
A, agreement; AKI, acute kidney injury; D, disagreement; E, equivocal; SIA, seek immediate admission; U, agreement with uncertain benefit; CKD 4/5, chronic kidney disease stage 4 or 5.
Blakem
an
T,etal.BM
J
Open
2016;6:e012865.doi:10.1136/bm
jopen-2016-012865
5
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 April 20, 2017 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
Table 4 Timeliness in response to AKI warning stage test results for adults in primary care—no acute illness
AKI warning stage 1 AKI warning stage 2 AKI warning stage 3
AKI with no
history of acute
illness
No
comorbidities
Chronic
heart
failure
CKD 4/5 or
renal
transplant
CKD 4/5
and chronic
heart
failure
No
comorbidities
Chronic
heart
failure
CKD 4/5 or
renal
transplant
CKD 4/5
and chronic
heart
failure
No
comorbidities
Chronic
heart
failure
CKD 4/5 or
renal
transplant
CKD 4/5
and chronic
heart failure
Potassium not
raised
SIA=A(1)
<6=A(1)
<24=E(6.5)
<72=E(7.5)
SIA=A(1)
<6=E(4)
<24=A(7)
<72=E(7)
SIA=A(1)
<6=E(4.5)
<24=A(8)
<72=E(4.5)
SIA=A(1)
<6=E(5)
<24=A(8)
<72=E(5)
SIA=E(1.5)
<6=E(6.5)
<24=E(6)
<72=E(1.5)
SIA=E(2.5)
<6=E(7)
<24=U(7)
<72=A(1)
SIA=E(5.5)
<6=E(7)
<24=D(6)
<72=A(1)
SIA=D(5)
<6=U(7)
<24=E(5)
<72=A(1)
SIA=E(7)
<6=A(7.5)
<24=E(2.5)
<72=A(1)
SIA=U(7)
<6=A(8)
<24=E(4)
<72=A(1)
SIA=A(7)
<6=U(7)
<24=A(1.5)
<72=A(1)
SIA=A(8)
<6=E(6.5)
<24=A(1)
<72=A(1)
Mild
hyperkalaemia
(5.5–5.9mmol/L)
SIA=A(1)
<6=E(3.5)
<24=A(8)
<72=E(6)
SIA=A(1)
<6=E(5)
<24=A(8)
<72=D(3)
SIA=A(1.5)
<6=E(5)
<24=A(8)
<72=E(1)
SIA=A(1)
<6=D(5.5)
<24=A(8)
<72=A(1)
SIA=E(2.5)
<6=E(6.5)
<24=E(7)
<72=E(2.5)
SIA=E(2.5)
<6=U(7)
<24=E(7)
<72=A(1)
SIA=D(5.5)
<6=U(7)
<24=D(5.5)
<72=A(1)
SIA=D(5.5)
<6=A(7.5)
<24=D(5.5)
<72=A(1)
SIA=U(7)
<6=A(7.5)
<24=E(1.5)
<72=A(1)
SIA=A(7)
<6=A(7.5)
SIA=A(8)
<6=E(7)
<24=A(1.5)
<72=A(1)
SIA=A(8)
<6=E(7.5)
<24=A(1)
<72=A(1)
<24=E(3)
<72=A(1)
Moderate
hyperkalaemia
(6.0–6.4 mmol/L)
SIA=E(3)
<6=A(7)
<24=E(7)
<72=A(1.5)
SIA=E(3.5)
<6=A(7)
<24=E(6)
<72=A(1)
SIA=E(6)
<6=A(8)
<24=D(5.5)
<72=A(1)
SIA=E(6)
<6=A(7.5)
<24=D(5.5)
<72=A(1)
SIA=E(4)
<6=A(8)
<24=D(6)
<72=A(1)
SIA=E(5.5)
<6=A(8)
<24=E(6)
<72=A(1)
SIA=E(6.5)
<6=A(8)
<24=E(3.5)
<72=A(1)
SIA=A(8)
<6=A(8)
SIA=A(8)
<6=A(7.5)
SIA=A(8)
<6=A(7.5)
SIA=A(9)
<6=E(6)
<24=A(1)
<72=A(1)
SIA=A(9)
<6=D(4.5)
<24=A(1)
<72=A(1)
<24=E(3)
<72=A(1)
<24=A(1.5)
<72=A(1)
<24=A(1.5)
<72=A(1)
Recent increase
diuretics/ACEI+
potassium not
raised
SIA=A(1)
<6=A(2)
<24=A(8)
<72=U(6)
SIA=A(1)
<6=E(3.5)
<24=U(6.5)
<72=D(6)
SIA=A(2)
<6=U(5.5)
<24=A(8)
<72=E(3)
SIA=A(2.5)
<6=E(5)
<24=A(8)
<72=A(2.5)
SIA=E(3)
<6=E(7)
<24=E(7)
<72=E(1)
SIA=E(3)
<6=U(7)
<24=U(7.5)
<72=E(1)
SIA=U(3)
<6=U(7)
<24=E(6.5)
<72=A(1)
SIA=U(4)
<6=A(7)
<24=D(5.5)
<72=A(1)
SIA=E(7)
<6=A(7.5)
<24=E(2)
<72=A(1)
SIA=A(7)
<6=A(7)
SIA=A(7)
<6=E(7)
<24=E(1)
<72=A(1)
SIA=A(7.5)
<6=U(7.5)
<24=A(1.5)
<72=A(1)
<24=E(3)
<72=A(1)
Recent increase
diuretics/ACEI
+mild
hyperkalaemia
SIA=A(1.5)
<6=E(4)
<24=A(8)
<72=E(5.5)
SIA=A(1.5)
<6=E(5)
<24=A(8)
<72=A(2.5)
SIA=A(2.5)
<6=E(7)
<24=A(7.5)
<72=A(2)
SIA=E(3)
<6=E(6)
<24=A(8)
<72=A(2)
SIA=A(3)
<6=U(7)
<24=E(6.5)
<72=A(1.5)
SIA=E(3)
<6=U(7)
<24=E(6.5)
<72=E(1.5)
SIA=U(4)
<6=A(7)
<24=E(5.5)
<72=A(1)
SIA=U(5)
<6=A(8)
<24=D(4)
<72=A(1)
SIA=A(7)
<6=A (7.5)
SIA=A(7)
<6=A(7)
SIA=A(7)
<6=E(7.5)
<24=A(1)
<72=A(1)
SIA=A(7.5)
<6=U(7.5)
<24=A (1.5)
<72=A(1)
<24=E(2)
<72=A(1)
<24=E(1.5)
<72=A(1)
Recent increase
diuretics/ACEI
+moderate
hyperkalaemia
SIA=E(3)
<6=A(7)
<24=E(7)
<72=A(1)
SIA=U(4)
<6=A(7.5)
<24=D(6.5)
<72=A(1)
SIA=U(5.5)
<6=A(8)
<24=D(6.5)
<72=A(1)
SIA=E(6)
<6=A(7)
<24=D(5)
<72=A(1)
SIA=E(3.5)
<6=A(8)
<24=D(6)
<72=A(1)
SIA=E(6.5)
<6=A(8)
<24=E(6)
<72=A (1)
SIA=U(7)
<6=A(8)
<24=E(3.5)
<72=A(1)
SIA=A(7)
<6=A(7.5)
SIA=A(8)
<6=U(7.5)
<24=A(1.5)
<72=A(1)
SIA=A(8)
<6=E(7)
<24=A(1)
<72=A(1)
SIA=A(8.5)
<6=E(7)
<24=A(1)
<72=A(1)
SIA=A(8)
<6=E(7)
<24=A(1)
<72=A(1)
<24=U(4)
<72=A(1)
Colour key: red: agreement that seeking immediate admission is an appropriate action; orange: agreement that responding in <6 hours is an appropriate action; brown: agreement that
responding in <24 hours is an appropriate action; no colour: no agreement on an appropriate action. Numerical value in brackets: median rating.
A, agreement; ACEI, ACE inhibitors; AKI, acute kidney injury; CKD 4/5, chronic kidney disease stage 4 or 5; D, disagreement; E, equivocal; SIA, seek immediate admission; U, agreement with
uncertain benefit.
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(10.4%) of the proposed actions for a scenario, there
was agreement of uncertain benefit.
The study was primarily undertaken to support the
development of new guidance on the response to AKI
warning stage test results for adults in primary care.
Tables 2–4 and the Results section focus on presenting
data for adults. Supplementary tables present data for a
child or young person as well as for adults with chronic
heart failure on an end of life care pathway.
Communication of an AKI warning stage test result to
primary care
Table 2 presents the data for the timeliness in communi-
cation of AKI warning stage test results for adults by
clinical pathology services to primary care. There was
agreement that delivery of AKI warning stage test results
through interruptive methods of communication (ie,
telephone result) from laboratories to primary care was
the appropriate next step for patients with: an AKI
warning stage 3 test result irrespective of potassium level;
an AKI warning stage 2 test result in the presence of
mild (K+ 5.5–5.9 mmol/L) or moderate hyperkalaemia
(K+ 6.0–6.4 mmol/L); and an AKI warning stage 1 test
result in the presence of moderate hyperkalaemia (K+
6.0–6.4 mmol/L).
Timeliness in clinician response to an AKI warning
stage test result
Data on the timeliness in clinician response to AKI
warning stage test results for adults in primary care are
presented in table 3 (in the context of acute illness) and
table 4 (no history of acute illness). Agreement was
reached on an appropriate next step for the majority of
clinical cases presented to panel members: 48 out of the
65 (73.8%) clinical cases relating to AKI test results in
the context of acute illness and 58 out of 72 (80.6%)
clinical cases for AKI test results with no history of acute
illness.
In the context of acute illness, there was a greater
level of uncertainty on the appropriate action for clinical
cases relating to AKI warning stage 1 test results, particu-
larly in the context of patients with chronic heart
failure. In the absence of acute illness, there was a
greater level of uncertainty on the appropriate next step
for clinical cases relating to AKI warning stage 2 test
results.
In the context of acute illness, waiting up to 72 hours
to respond to an AKI warning stage test result was
deemed an inappropriate action in 62 out of 65 (94.5%)
clinical cases tested. In the absence of acute illness,
waiting up to 72 hours was deemed inappropriate in 56
out of the 72 (77.8%) clinical cases, with uncertainty for
this timeframe tending to relate to AKI warning stage 1
test results.
There was agreement that a clinician response was
required within 6 hours, or less, in 39 out of 40 (97.5%)
clinical cases relating AKI warning stage test results in the
presence of moderate hyperkalaemia (K+ 6.0–6.4 mmol/L).
These findings included agreement to seek immediate
admission if moderate hyperkalaemia was present in the
context of AKI warning stage 3 results, AKI warning stage
2 results in the context of acute illness and AKI warning
stage 1 results in the context of acute illness associated
with poor oral intake/urine output.
There was uncertainty on the appropriate response to
AKI warning stage test results generated for patients with
chronic heart failure on an end of life care pathway,
though waiting up to 72 hours to respond to these test
results was deemed an inappropriate next step.
DISCUSSION
Principal findings
The introduction of warning stage test results based on a
national AKI algorithm is a major patient safety initiative
across the NHS in England.15 However, its implementa-
tion in primary care is at a period in time where clinical
workload is deemed to be reaching saturation point.36
The study is an important starting point in terms of navi-
gating the challenges of addressing the harm and costs
associated with AKI while avoiding the creation of addi-
tional workload for professionals and unnecessary
burden on patients.37 Through use of rigorous consen-
sus methods, the findings highlight clinical scenarios
where interruptive methods of communication (ie, tele-
phoning a test result) by clinical pathology services to
primary care are considered to be appropriate. There
was also agreement in the majority of clinical cases in
terms of determining the timeliness in response to an
AKI warning stage test result by a clinician in primary
care. In the main, waiting up to 72 hours was deemed
an inappropriate response. The findings from the study
have informed the development and recent publication
of NHS England Think Kidneys guidance (https://
http://www.thinkkidneys.nhs.uk/aki/resources/primary-
care/).33
Strengths and weaknesses of this study
The study used systematic RAND/UCLA consensus
methods to optimise the development of guidance for
clinicians on how to respond to AKI warning stage test
results for adults in primary care.29 Investment in ‘over-
coming questions about the legitimacy of new guidelines’
is important to ensure successful implementation.38 A key
feature of the study was to maximise the utility of AKI
alerts and minimise the potential for burden on patients
and health professionals. Efforts to achieve this included
engaging primary care clinicians who represented con-
cerns about medicalisation and overdiagnosis.35
Multiple scenarios were tested through use of RAMs.29
Key features of these scenarios were identified through
identification and comparison of existing relevant guid-
ance documents. Cross-referencing and integrating dif-
ferent guidelines may address challenges of clinical
decision-making in primary care, particularly for patients
with multimorbidity.39 For example, rather than treating
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results in isolation, the methodological approach enabled
AKI warning stage test results to be considered in the
context of hyperkalaemia. The results offer a platform to
inform alignment in guidance developed by NHS
England Think Kidneys Programme, the Royal College of
Pathologists and the UK Renal Association.33 34
AKI is a clinical syndrome and AKI warning stage test
results need to be considered with an understanding of
the clinical context in which they were taken.4 The
UCLA/RAND consensus process aimed to provide face
validity regarding the timeliness in response to AKI
warning stage test results by clinicians based on the
assumption that all the relevant clinical information was
available. There is evidence of the predictive validity of
quality indicators developed through the RAM.32 40 In
terms of developing ‘timeliness in response’ to AKI test
results as an indicator of patient safety in primary care,
future research needs to provide evidence of acceptabi-
lity, feasibility, reliability, sensitivity to change and pre-
dictive validity.32
Although a range of clinically relevant scenarios were
considered, in terms of burden on RAND/UCLA panel-
lists, it was not feasible to test all major comorbidity
groups (eg, patients with type 2 diabetes, patients receiv-
ing cancer treatment and not on an end of life care
pathway). In addition, developing scenarios for working
hours and out of hours may have produced greater
clarity on timeliness in response though would have also
lengthened the ratings process for panel members with
the potential for ‘cognitive strain’.41 On balance, the
chosen response times for rating (ie, seek immediate
admission; respond within 6 hours; respond within
24 hours; respond within 72 hours) sought to evaluate
appropriate actions taking into account key time frames
in current clinical practice (eg, respond within 6 hours
in order to determine whether appropriate to be seen
within working hours, or before next day if knowledge
of test result during out of hours; respond within
72 hours to determine if appropriate to wait until
Monday if knowledge of a test result on Friday after-
noon/evening).
Though the study sought clarity on ‘necessary’ next
steps conducted under ideal conditions, it is hoped that
the subsequent published guidance will seek to drive
system change to better support clinician decision-
making, both for in and out of hours care. Developing
robust systems for managing laboratory results is deemed
key to ensuring patient safety in general practice.42
Comparison with other studies
The introduction of AKI as a new classification system
has both the potential to structure and constrain the
delivery of acute illness care.4 43 Although AKI alerts are
a potential driver for improving patient safety, AKI is a
clinical diagnosis and diagnostic accuracy is dependent
on the clinician interpreting the test result in the
context of an individual patient. This includes
recognising the potential for ‘false positives’ such as
cases of misclassified CKD.15 19 20 An assessment of the
sensitivity of the NHS England AKI algorithm has been
carried out in secondary care but so far, there remain
little data on either its specificity or its real-time use in
primary care.19 A retrospective review of electronic
medical records would help estimate the diagnostic
AKI error rate as well as determine the incidence and
factors associated with missed diagnostic and manage-
ment opportunities.44
In the majority of UCLA/RAND clinical cases tested
through a multidisciplinary professional panel, a wait of
up to 72 hours to respond to an AKI warning stage test
result was considered to be inappropriate. This is a
potentially important marker of patient safety and
requires further evaluation. Caution is required inter-
preting an AKI warning stage test result in primary care
as AKI diagnostic and staging criteria are based on
changes in serum creatinine by >26 µmol/L within the
previous 48 hours, or an increase in serum creatinine by
≥1.5 times baseline that is known or presumed to have
occurred within the prior 7 days.4 15 Currently, unlike
the hospital setting, ‘baseline’ creatinine levels for com-
parison are less likely to have taken place within these
time periods, reiterating the importance that AKI is a
clinical (not merely a biochemical) diagnosis that
requires clinician review in order to place a test result in
context.
Though there is evidence that AKI is associated with
adverse clinical outcomes, the majority of the studies
informing the development of the KDIGO classification
system for AKI were based on critical care databases.45
As such, its application may not necessarily be generalis-
able to the primary care setting.45 However, irrespective
of whether an AKI warning stage test result leads to con-
firmation of AKI or alternatively flags CKD progression,
there is evidence to indicate that the e-alerts are still
likely to ‘identify patients at risk of poor outcomes’ in
terms of non-recovery, chronic renal replacement
therapy and long-term mortality.17 46
Implications for clinicians, policymakers and future
research
There was greater uncertainty in how to respond to AKI
warning stage test results for people with chronic heart
failure, a population who have an increased morbidity
and mortality and who account for ∼5% of emergency
hospital admissions.47 This highlights a need for better
evidence to support response to changes in serum cre-
atinine for these patients.48 49 As indicated by the
European Society of Cardiology Heart Failure (ESC)
guidelines (2016), increases in serum creatinine are not
always the main clinical priority, ‘especially when they
are accompanied by appropriate decongestion, diuresis
and haemoconcentration’49—although this statement
was in the context of acute heart failure in hospital; data
on the prognostic importance of changes in kidney
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function during treatment of heart failure in primary
care are lacking. The ESC guidelines recommend that
‘when large increases in serum creatinine occur, care
should be taken to evaluate the patient thoroughly and
should include assessment of a possible renal artery sten-
osis, excessive hypervolaemia or hypovolaemia, concomi-
tant medication and hyperkalaemia, which frequently
coincides with worsening renal function’.49 This again
highlights the importance of ‘treating the patient and
not the test result’ and of comparing the test result with
current and previous creatinine levels.33 48 Knowing the
reason for why kidney function tests were taken is of
primary importance. Were they taken in the context of:
routine chronic disease monitoring, pharmacotherapy
monitoring (eg, dose adjustment) or to support
decision-making for patients presenting with a history of
acute illness?33
Effective minimally disruptive medicine is a key prin-
ciple underpinning care delivery.37 Resourcing initiatives
to address the growth in demand for urgent care ser-
vices is a priority, particularly with an ageing population
with increasing care needs.50 51 Rather than being an
additional burden, targeting AKI may provide an
approach to better assessment and management of
acute illness across the primary/secondary care inter-
face.52 As stated by Guthrie et al,39 people with complex
comorbidities ‘have patterns of illness that do not neatly
fit disease categories, in which case syndrome focused
guidance or tools will often be relevant’.39 Aligned with
the implementation of the national AKI algorithm and
professional guidance, resourcing patient and public
involvement is critical to the development of a more
responsive urgent care service.50 51 However, while dia-
logue about the importance of kidney health may
provide a platform to support self-management, this cur-
rently remains limited.33 53–56 Evidence exists that only
one in two people are aware that the kidneys make
urine and that only 12% of the population have knowl-
edge that the kidneys have a role in processing
medicines.57
CONCLUSIONS
Tackling the harm associated with care complicated by
AKI is a global priority.2 In England, a national AKI algo-
rithm is being introduced across the to drive this
change.15 However, in a context where clinical workload
in English general practice is reaching saturation
point,36 there is a need to maximise its clinical utility
and minimise the potential for burden on clinicians and
patients.37 The study sought to address this challenge
and the findings have informed the development of
guidance to support a timely and calibrated response to
AKI warning stage test results for adults in primary care.
Further research is needed to support effective imple-
mentation, with a view to examine the effect on health
outcomes and costs.
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